Daniel Kuhn

Dr. Daniel Kuhn

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2024 in Nature Methods
Verified
Journal Article
Open access
PDF file
SCSrinivas Niranj Chandrasekaran
Srinivas Niranj Chandrasekaran
BCBeth A. Cimini
Beth A. Cimini
AGAmy Goodale
Amy Goodale
LMLisa Miller
Lisa Miller
MKMaria Kost-Alimova
Maria Kost-Alimova
ACAnne E. Carpenter
Anne E. Carpenter
The identification of genetic and chemical perturbations with similar impacts on cell morphology can elucidate compounds’ mechanisms of action or novel regulators of genetic pathways. Research on methods for identifying such similarities has lagged due to a lack of carefully designed and well-annotated image sets of cells treated with chemical and genetic perturbations. Here we create such a Resource dataset, CPJUMP1, in which each perturbed gene’s product is a known target of at least two chemical compounds in the dataset. We systematically explore the directionality of correlations among perturbations that target the same protein encoded by a given gene, and we find that identifying matches between chemical and genetic perturbations is a challenging task. Our dataset and baseline analyses provide a benchmark for evaluating methods that measure perturbation similarities and impact, and more generally, learn effective representations of cellular state from microscopy images. Such advancements would accelerate the applications of image-based profiling of cellular states, such as uncovering drug mode of action or probing functional genomics.

28 August 2023 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
DBDavide Boldini
Davide Boldini
FGFrancesca Grisoni
Francesca Grisoni
DKDaniel Kuhn
Daniel Kuhn
LFLukas Friedrich
Lukas Friedrich
SSStephan A. Sieber
Stephan A. Sieber
Decision tree ensembles are among the most robust, high-performing and computationally efficient machine learning approaches for quantitative structure–activity relationship (QSAR) modeling. Among them, gradient boosting has recently garnered particular attention, for its performance in data science competitions, virtual screening campaigns, and bioactivity prediction. However, different variants of gradient boosting exist, the most popular being XGBoost, LightGBM and CatBoost. Our study provides the first comprehensive comparison of these approaches for QSAR. To this end, we trained 157,590 gradient boosting models, which were evaluated on 16 datasets and 94 endpoints, comprising 1.4 million compounds in total. Our results show that XGBoost generally achieves the best predictive performance, while LightGBM requires the least training time, especially for larger datasets. In terms of feature importance, the models surprisingly rank molecular features differently, reflecting differences in regularization techniques and decision tree structures. Thus, expert knowledge must always be employed when evaluating data-driven explanations of bioactivity. Furthermore, our results show that the relevance of each hyperparameter varies greatly across datasets and that it is crucial to optimize as many hyperparameters as possible to maximize the predictive performance. In conclusion, our study provides the first set of guidelines for cheminformatics practitioners to effectively train, optimize and evaluate gradient boosting models for virtual screening and QSAR applications. Graphical abstract

15 February 2022 in Nature Reviews Chemistry
Verified
Journal Article
Closed access
PDF file
SASuzanne Ackloo
Suzanne Ackloo
RARima Al-Awar
Rima Al-Awar
RARommie Amaro
Rommie Amaro
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
HAHatylas Azevedo
Hatylas Azevedo
TWTimothy M. Willson
Timothy M. Willson

24 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SCSrinivas Niranj Chandrasekaran
Srinivas Niranj Chandrasekaran
JAJeanelle Ackerman
Jeanelle Ackerman
EAEric Alix
Eric Alix
DAD. Michael Ando
D. Michael Ando
JAJohn Arevalo
John Arevalo
ACAnne E. Carpenter
Anne E. Carpenter
Image-based profiling decodes complex cellular states for high-impact biological and therapeutic applications, yet a large, public reference dataset of chemical perturbations has been lacking. We present Cell Painting images and 1.53 billion single-cell profiles for 115,796 compounds in human osteosarcoma cells, generated by the Joint Undertaking for Morphological Profiling (JUMP)-Cell Painting Consortium of 18 industry and non-profit partners. Despite technical variability across 12 data-generating laboratories, more than 15% of compounds show statistically significant phenotypic activity, reproducibility drops only 34% versus single-laboratory data, and compounds sharing biological targets often show similar image-based profiles. JUMP establishes a validated public reference resource that brings image-based profiling on par with genomics and transcriptomics. The dataset, shared alongside previously released genetic perturbation data in the Cell Painting Gallery, is a powerful predictive engine for the impact, mechanism, targets and activities of compounds, fundamentally accelerating chemical and cell biology and early-stage drug development.

5 March 2025 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
THThierry Hanser
Thierry Hanser
EAErnst Ahlberg
Ernst Ahlberg
AAAlexander Amberg
Alexander Amberg
LALennart T. Anger
Lennart T. Anger
CBChris Barber
Chris Barber
TYTomoya Yukawa
Tomoya Yukawa

15 March 2024 in ACS Central Science
Verified
Journal Article
Open access
DBDavide Boldini
Davide Boldini
LFLukas Friedrich
Lukas Friedrich
DKDaniel Kuhn
Daniel Kuhn
SSStephan A. Sieber
Stephan A. Sieber
Efficient prioritization of bioactive compounds from high throughput screening campaigns is a fundamental challenge for accelerating drug development efforts. In this study, we present the first data-driven approach to simultaneously detect assay interferents and prioritize true bioactive compounds. By analyzing the learning dynamics during training of a gradient boosting model on noisy high throughput screening data using a novel formulation of sample influence, we are able to distinguish between compounds exhibiting the desired biological response and those producing assay artifacts. Therefore, our method enables false positive and true positive detection without relying on prior screens or assay interference mechanisms, making it applicable to any high throughput screening campaign. We demonstrate that our approach consistently excludes assay interferents with different mechanisms and prioritizes biologically relevant compounds more efficiently than all tested baselines, including a retrospective case study simulating its use in a real drug discovery campaign. Finally, our tool is extremely computationally efficient, requiring less than 30 s per assay on low-resource hardware. As such, our findings show that our method is an ideal addition to existing false positive detection tools and can be used to guide further pharmacological optimization after high throughput screening campaigns.